Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene In Licensing "Discussions" On Thalomid Risk Management Patents

This article was originally published in The Pink Sheet Daily

Executive Summary

Thalidomide STEPS program patents and increasing emphasis on restricted drug distribution systems create "potential licensing and revenue opportunities," Celgene says. The patents are blocking implementation of revised risk management plans for Accutane and isotretinoin generics.

You may also be interested in...



Allergan To Discuss Tazoral Psoriasis Non-Inferiority Study With FDA

FDA deems oral tazarotene "not approvable." In addition to a non-inferiority study, Allergan must develop an "acceptable" risk management program and resolve manufacturing problems.

Allergan To Discuss Tazoral Psoriasis Non-Inferiority Study With FDA

FDA deems oral tazarotene "not approvable." In addition to a non-inferiority study, Allergan must develop an "acceptable" risk management program and resolve manufacturing problems.

Revised Accutane Label Describes Lack Of PK Effect On Ortho-Novum

A study of 31 women showed Accutane at the recommended dose did not induce clinically relevant changes in the pharmacokinetics of the oral contraceptive. Accutane's "black box" warning concerning possible interactions between isotretinoin and oral contraceptives remains in labeling.

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel